Strong CIDP Launch Performance
The CIDP launch exceeded expectations with over 300 patients on VYVGART Hytrulo by the end of the quarter, achieving revenue similar to the first MG quarter. 85-90% of these patients switched from IVIg, indicating strong market acceptance.
Record Revenue Growth
Total operating income for Q3 2024 was $589 million, with product net sales of $573 million, representing 20% quarter-over-quarter growth and 74% growth compared to the prior year quarter.
VYVGART's Continued Success in MG
VYVGART continues to drive significant growth in MG, with new prescribers and patients, expanding its market presence. Over 60% of new patients are coming from oral treatments.
International Expansion
VYVGART is now available to over 80% of the gMG population in the EU, and regulatory reviews for CIDP are ongoing in China, Japan, and Europe with approvals expected in 2025.
Positive Financial Outlook
The company reported a quarterly profit after tax of $91 million and a cash balance of $3.4 billion, with unchanged SG&A and R&D spend guidance for 2024.